In Naiyer’s study, the result of the treatment of PD-1 targeting antibody pembrolizumab in NSCLC described that a higher burden of nonsynonymous tumors is correlated with a better response and PFS [70]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.